[Beta receptor block versus calcium antagonism. A comparative study of bopindolol and nifedipine with special regard to quality of life].
203 patients with a diastolic blood pressure higher than 100 mmHg were included in a randomized, double-blind trial to compare the antihypertensive efficacy of different daily dosages of bopindolol (Wandonorm) (0.05 mg, 0.5 mg, 1 mg, 2 mg) and nifedipine (2 x 20 mg). After 4 weeks of therapy blood pressure normalization could be achieved in 23.7% (0.05 mg), 32.5% (0.5 mg), 67.5% (1 mg), 64.1% (2 mg) and 59.0% (nifedipine) of the patients, respectively. In a subgroup of 159 patients the study was continued with an 8-week dose titration and a 16-week observation. At the end of the study blood pressure normalization was achieved in 91% and 94% of the patients treated with nifedipine and bopindolol, respectively. Most patients of the bopindolol-group needed 1 mg once daily as compared to those on the nifedipine who required 20 mg b.i.d. Because of intolerable side effects therapy was discontinued in 3 out of 162 patients on bopindolol and in 3 out of 41 patients on nifedipine. As compared to nifedipine the tolerance of bopindolol was judged significantly superior because tiredness and dizziness (32% vs 9%) and leg edema (20% vs. 6%) were recorded much more frequently in nifedipine treated patients. In 135 elderly patients "quality of life" was assessed upon by use of the "Nuremberg-Alters-Selbstbeurteilungs-Skala" (NAS), which refers to social contacts, mental and physical performance, sleep disturbances and general well-being.(ABSTRACT TRUNCATED AT 250 WORDS)
Welzel
D
D
Lehrstuhl für Pharmakologie der Universität Regensburg.
Bräutigam
M
M
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000009:adverse effects / Q000627:therapeutic use*; D010869:Pindolol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011788:Quality of Life; D011897:Random Allocation
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D010869:Pindolol; D009543:Nifedipine; C036007:bopindolol
beta-Rezeptorblockade versus Kalzium-Antagonismus. Eine vergleichende Studie über Bopindolol und Nifedipin unter besonderer Berücksichtigung der Lebensqualität.